down arrow

Perrigo Co. Plc

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: IE00BGH1M568
USD
14.72
-0.36 (-2.39%)

Jan 23

NYS

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

14.6815.17

52 Week

12.1830.93
Valuation
Technical
Day's Volume

CASH

2.1 M

Shareholding (Sep 2025)

FII

13.41%

Held by 148 FIIs

DII

32.05%

Held by 73 DIIs

Promoter

0.00%

How big is Perrigo Co. Plc?

22-Jun-2025

As of Jun 18, Perrigo Co. Plc has a market capitalization of 3,611.53 million, with net sales of 4,335.20 million and a net profit of -164.60 million over the latest four quarters.

Market Cap: As of Jun 18, Perrigo Co. Plc has a market capitalization of 3,611.53 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Perrigo Co. Plc reported net sales of 4,335.20 million and a net profit of -164.60 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 4,319.40 million and total assets of 9,647.70 million.

View full answer

What does Perrigo Co. Plc do?

22-Jun-2025

Perrigo Co. Plc provides over-the-counter self-care and wellness solutions in the Pharmaceuticals & Biotechnology industry, with a market cap of approximately $3.61 billion. As of March 2025, it reported net sales of $1.04 billion and a dividend yield of 0.07%.

Overview:<BR>Perrigo Co. Plc engages in providing over-the-counter (OTC) self-care and wellness solutions within the Pharmaceuticals & Biotechnology industry, operating in the small-cap market.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1,044 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 0 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 3,611.53 Million (Small Cap)<BR><BR>Key Metrics:<BR>P/E: NA <BR>Industry P/E: NA <BR>Dividend Yield: 0.07% <BR>Debt Equity: 0.74 <BR>Return on Equity: -0.63% <BR>Price to Book: 0.83<BR><BR>Contact Details:<BR>Address: The Sharp Building, Hogan Place, DUBLIN None : D02 TY74 <BR>Tel: ['353 1 7094000', '1 269 6863373'] <BR>Website: https://www.perrigo.com/

View full answer

Who are in the management team of Perrigo Co. Plc?

22-Jun-2025

As of March 2022, the management team of Perrigo Co. Plc includes President and CEO Mr. Murray Kessler, along with Board members Mr. Orlando Ashford, Ms. Katherine Doyle, Mr. Bradley Alford, Mr. Rolf Classon, and Ms. Adriana Karaboutis, the latter three serving as Independent Directors.

As of March 2022, the management team of Perrigo Co. Plc includes Mr. Murray Kessler, who serves as the President, Chief Executive Officer, and Director. Additionally, the Board of Directors comprises Mr. Orlando Ashford, Ms. Katherine Doyle, Mr. Bradley Alford, Mr. Rolf Classon, and Ms. Adriana Karaboutis, with the latter three serving as Independent Directors.

View full answer

Is Perrigo Co. Plc overvalued or undervalued?

20-Sep-2025

As of August 2, 2024, Perrigo Co. Plc's valuation has shifted to risky due to overvaluation concerns, highlighted by a non-applicable P/E ratio from losses, a low ROE of -0.63%, and significant underperformance against the S&P 500, making it less appealing compared to peers like Exelixis, Inc. and Alkermes Plc.

As of 2 August 2024, the valuation grade for Perrigo Co. Plc has moved from fair to risky, indicating a deterioration in its investment appeal. The company appears to be overvalued, particularly given its P/E ratio is not applicable due to losses, while its Price to Book Value stands at 0.82, suggesting it is trading below its book value, but this is overshadowed by a high EV to EBITDA of 9.71 and a low ROE of -0.63%. <BR><BR>In comparison to its peers, Perrigo's valuation metrics are concerning; for instance, Exelixis, Inc. has a more favorable P/E of 15.81 and an EV to EBITDA of 11.97, while Alkermes Plc also shows stronger fundamentals with a P/E of 13.77 and an EV to EBITDA of 9.41. Furthermore, Perrigo's stock has significantly underperformed against the S&P 500 over multiple periods, with a year-to-date return of -16.84% compared to the S&P 500's 12.22%, reinforcing the notion that the stock is not a compelling investment at this time.

View full answer

Is Perrigo Co. Plc technically bullish or bearish?

20-Sep-2025

As of September 3, 2025, Perrigo Co. Plc's technical trend has shifted to bearish, indicated by negative signals from MACD, Bollinger Bands, and moving averages, while it has underperformed the S&P 500 with a year-to-date return of -16.84%.

As of 3 September 2025, the technical trend for Perrigo Co. Plc has changed from mildly bearish to bearish. The current technical stance is bearish with a strong indication from multiple indicators: both the weekly and monthly MACD are bearish, Bollinger Bands are bearish across both time frames, and the daily moving averages also reflect a bearish trend. The KST shows a mildly bullish signal on the monthly, but this is overshadowed by the overall bearish sentiment. Additionally, the Dow Theory indicates a mildly bearish stance on both weekly and monthly analyses. <BR><BR>Perrigo has significantly underperformed compared to the S&P 500, with a year-to-date return of -16.84% versus the S&P 500's 12.22%, and a one-year return of -24.08% compared to the S&P 500's 17.14%.

View full answer

Compare Perrigo Co. Plc with Similar Stocks

Organon & Co.Apellis Pharmaceuticals, Inc.Alkermes Plc
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

1

Company has a low Debt to Equity ratio (avg) at times

 
2

Positive results in Jun 25

3

Risky -

4

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 2,052 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.73

stock-summary
Return on Equity

0.63%

stock-summary
Price to Book

0.46

Revenue and Profits:
Net Sales:
1,043 Million
(Quarterly Results - Sep 2025)
Net Profit:
13 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-31.53%
0%
-31.53%
6 Months
-47.65%
0%
-47.65%
1 Year
-40.53%
0%
-40.53%
2 Years
-55.73%
0%
-55.73%
3 Years
-60.39%
0%
-60.39%
4 Years
-62.1%
0%
-62.1%
5 Years
-66.0%
0%
-66.0%

Perrigo Co. Plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Perrigo Co. Stock Hits Day Low of $15.05 Amid Price Pressure

Perrigo Co. Stock Hits Day Low of $15.05 Amid Price Pressure

Perrigo Co. Plc has faced substantial stock volatility, with significant declines over various timeframes, including a year-to-date drop of over 41%. The company reported a net profit loss and a sharp decrease in pre-tax profit, alongside a concerning debt-to-equity ratio and low return on equity.

Read full news article
Perrigo Co. Plc Hits New 52-Week Low at USD 20.18

Perrigo Co. Plc Hits New 52-Week Low at USD 20.18

Perrigo Co. Plc has reached a new 52-week low, reflecting a significant decline in its performance over the past year. The company faces ongoing financial challenges, including a substantial net profit loss and rising raw material costs, contributing to its underperformance compared to market benchmarks.

Read full news article
Perrigo Co. Hits 52-Week Low at $20.26 Amid Financial Struggles

Perrigo Co. Hits 52-Week Low at $20.26 Amid Financial Struggles

Perrigo Co. Plc has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. The company faces financial challenges, including a substantial net profit loss and limited profitability, while its performance has consistently underperformed compared to the S&P 500.

Read full news article

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
-3.14%
EBIT Growth (5y)
-4.98%
EBIT to Interest (avg)
1.61
Debt to EBITDA (avg)
4.82
Net Debt to Equity (avg)
0.74
Sales to Capital Employed (avg)
0.52
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
3.50%
ROE (avg)
1.14%

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.82
EV to EBIT
18.06
EV to EBITDA
9.71
EV to Capital Employed
0.90
EV to Sales
1.58
PEG Ratio
NA
Dividend Yield
0.08%
ROCE (Latest)
4.98%
ROE (Latest)
-0.63%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
Bearish
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 94 Schemes (54.51%)

Foreign Institutions

Held by 148 Foreign Institutions (13.41%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is -1.25% vs 1.18% in Jun 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 2,640.00% vs -600.00% in Jun 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,043.10",
          "val2": "1,056.30",
          "chgp": "-1.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "192.30",
          "val2": "154.00",
          "chgp": "24.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "54.00",
          "val2": "53.50",
          "chgp": "0.93%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-21.40",
          "val2": "-1.10",
          "chgp": "-1,845.45%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "12.70",
          "val2": "-0.50",
          "chgp": "2,640.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "102.50%",
          "val2": "64.10%",
          "chgp": "3.84%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -6.04% vs 4.60% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -3,552.27% vs 96.64% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4,373.70",
          "val2": "4,655.10",
          "chgp": "-6.04%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "644.00",
          "val2": "641.70",
          "chgp": "0.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "248.50",
          "val2": "224.70",
          "chgp": "10.59%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-173.10",
          "val2": "-97.30",
          "chgp": "-77.90%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-160.70",
          "val2": "-4.40",
          "chgp": "-3,552.27%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "72.70%",
          "val2": "60.60%",
          "chgp": "1.21%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQstock-summary

Sep'25
Jun'25
Change(%)
Net Sales
1,043.10
1,056.30
-1.25%
Operating Profit (PBDIT) excl Other Income
192.30
154.00
24.87%
Interest
54.00
53.50
0.93%
Exceptional Items
-21.40
-1.10
-1,845.45%
Consolidate Net Profit
12.70
-0.50
2,640.00%
Operating Profit Margin (Excl OI)
102.50%
64.10%
3.84%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Sep 2025 is -1.25% vs 1.18% in Jun 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is 2,640.00% vs -600.00% in Jun 2025

All Quarterly Resultsstock-summary

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
4,373.70
4,655.10
-6.04%
Operating Profit (PBDIT) excl Other Income
644.00
641.70
0.36%
Interest
248.50
224.70
10.59%
Exceptional Items
-173.10
-97.30
-77.90%
Consolidate Net Profit
-160.70
-4.40
-3,552.27%
Operating Profit Margin (Excl OI)
72.70%
60.60%
1.21%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -6.04% vs 4.60% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -3,552.27% vs 96.64% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Perrigo Co. Plc stock-summary
stock-summary
Perrigo Co. Plc
Pharmaceuticals & Biotechnology
Perrigo Co. Plc engages in providing over-the-counter (OTC) self-care and wellness solutions. Its solutions enhance individual well-being by enabling consumers to proactively prevent or treat conditions that can be self-managed. The Company operates through three segments: Consumer Self-Care Americas, Consumer Self-Care International and Prescription Pharmaceuticals. The Consumer Self-Care Americas segment comprises the store brand consumer self-care business in the United States (U.S.), Mexico and Canada. The Consumer Self-Care International segment includes the branded consumer self-care business in Europe, along with generic consumer-focused businesses in the United Kingdom (U.K.) and Australia. The Prescription Pharmaceuticals segment commercializes and manufactures generic prescription products in the U.S. and diagnostic products in Israel.
Company Coordinates stock-summary
Company Details
The Sharp Building, Hogan Place , DUBLIN None : D02 TY74
stock-summary
Tel: 353 1 70940001 269 6863373
stock-summary
https://www.perrigo.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Download on App Store
Get it on Google Play
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."